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Objective. Ewing’s sarcoma of the kidney is rare and is usually found in young adults. We present here a single case study of
E w i n g ’ ss a r c o m af o u n di na ne l d e r l ym a n .Material and methods. A 73-year-old man underwent routine surgery for hydrocoele
of the testis. He developed urinary obstruction symptoms, and radiological examinations revealed a tumour in the right kidney.
Results. Microscopical, immunohistochemical, and molecular pathological analysis of the tumour was consistent with Ewing’s
sarcoma. FISH showed rearrangement of chromosomes 22q12 (EWSR1). The patient subsequently underwent nephrectomy
followed by 6 adjuvant chemotherapy cycles. Follow-up after 7 monthsshows no recurrence. Conclusion.T h i sc a s er e p o r tp r e s e n t s
not only the rare ﬁnding of Ewing’s sarcoma in the kidney, but also the occurrence of this tumour entity in an elderly patient.
Treatment optionsforthediﬀerenttypes ofrenaltumoursare vastlydiﬀerent andtheneedforacorrect diagnosisis,therefore, vital.
1.Introduction
Ewing’s sarcomas are high-grade malignant tumours typi-
cally found in children and adolescents and are uncommon
after the age of thirty. These tumours belong to the family
of small-round cell tumours and are of neuroectodermal
origin. They are mostly localized in bone or soft tissue of the
extremities, the pelvis and central axis, and are rarely found
in visceral organs.
E w i n g ’ ss a r c o m a so ft h ek i d n e y sa r er a r ea l t h o u g ht h e
incidence is increasing [1]. In this case report, we present an
elderly patient with Ewing’s sarcoma of the kidney.
2.MaterialandMethods
2.1. Medical History. A 73-year-old man underwent surgery
f o rh y d r o c o e l eo ft h et e s t i s .H eh a dn oo t h e rs i g n i ﬁ c a n t
medical history. Due to postoperative symptoms of urinary
obstruction, a CT scan was performed revealing a contrast
ﬁlling tumour in the right renal pelvis and perirenal fatty
tissue (Figure 1). There were no metastases present on CT
imaging of thorax, abdomen, and pelvis. Fine needle biopsy
withimmunohistologicalanalysisshowed malignanttumour
of small, round cells consistent with Ewing’s sarcoma. He
subsequently underwent right sided nephrectomy. Postoper-
ative recovery was uneventful. The patient received adjuvant
chemotherapy according to a modiﬁed ISG/SSG(Italian Sar-
coma Group/Scandinavian Sarcoma Group). Ewing protocol
treatment regimen [2] due to his age and slightly decreased
kidney function following nephrectomy (Table 1).
However, an individual assessment should always be
done striving to give the same treatment regardless of the
patient’sage.Ourpatientreceivedatotalofsixchemotherapy
cycles. He experienced fatigue from the 6-month-long treat-
ment regimen and did not wish to continue. His 7-month-
response evaluations with CT scan and chest X-ray showed
no sign of recurrence.
3.Results
3.1. Pathological Findings
3.1.1. Gross Examination. Gross examination showed a large
tumour in the right kidney extending into the renal pelvis
and through the renal capsule into perirenal fat, but not
through the Gerota’s fascie.2 Sarcoma
Figure 1: Contrast-enhanced CT abdomen and pelvis showing a
tumour with central necrosis originating from the right renal pelvis
and protruding into perirenal fat medially. There is slight dilatation
of the superior and inferior calyces.
Table 1: Total dose of chemotherapy drugs per square meter.
mg/m2
Vincristine 3. 1
Etoposide 302
Actinomycin D 1,04
Cyclofosfamide 1677
Doxorubicin 265
Ifosfamide 12369
3.1.2. Microscopic Examination. The tumour consisted of
solidly packed, strikingly uniform small round cells with
scanty, pale cytoplasm and round to oval nuclei with sharp
borders and one to two small nucleoli (Figure 2).
3.1.3.ImmunohistochemicalAnalysis. Immunohistochemical
analysisshowedpositivestainingforvimentin,CD99andCD
117(Figure 3).The tumourcellswere negative forWT-1, Fli-
1, AE1/AE3, MYF-4, desmin, synaptophysin, chromogranin,
S-100, CD56, CD3, TdT, and CD20.
3.1.4. Molecular Pathological Findings. FISH showed rear-
rangement of chromosomes 22q12 (EWSR1). Real-time RT-
PCR showed EWSR-1-FLI1 or EWSR1-ERG genfusion con-
sistent with Ewing’s sarcoma, supporting the FISH ﬁndings.
4.Discussion
Ewing’s sarcoma of the kidney is rare. The majority are seen
in young adults with a mean age of presentation between 28
and 34 years (range 4–69 years), and a slight male predom-
inance [3]. In Norway, there are 5–10 new reported cases
of Ewing’s sarcomas (all locations) annually (Norwegian
Cancer Registry).
Figure 2:Typicalhistologicalspecimen which showssheetsofsmall
round uniform cells without clear cell boundaries and round to
oval nuclei with ﬁnely dispersed chromatin and one-to-two small
nucleoli (HE).
Figure 3: Immunohistochemical analysis shows uniform, strong
positive staining for CD99.
Ewing’s sarcoma (or Primitive Neuro Ectodermal Tum-
our, PNET) belongs to a family of small round-cell tumours
known as “The Ewing family of tumours.” They are derived
from neuroectodermal cells and are localized both insoft tis-
sue, visceral organs, and bone, the latter more commonly.
PNET’s can occur in numerous visceral organs including
urogenital, intra-abdominal and intrathoracic organs, with
kidney being the most common [4, 5].
Renal cell carcinoma is the most common renal tumour
andaccountsforapproximately85%ofallrenaltumoursand
2% of all new cancer cases in Norway according to data from
the Norwegian Cancer Registry; hence, renal cell carcinoma
has to be ruled outwhen ﬁnding a renal tumourin an elderly
patient (>50 years of age). If the tumour shows a small
round-cell pattern as in our case, the diﬀerential diagnosis
ranges from malignant lymphomas, small cell carcinoma,
small cell osteosarcoma, rhabdomyosarcoma, synovial sar-
coma, and desmoplastic small round-cell tumours.
When diagnosing Ewing’s sarcoma, the combination of
morphological ﬁndings, immunohistochemical analyses,
and genetic changes together forms the base of the diagnosis.
Our patient had a tumour that consisted of small round cellsSarcoma 3
which stained positive for CD99. FISH showed the classic
rearrangementthatisseeninEwing’ssarcoma, andPCRcon-
ﬁrmed this ﬁnding.
Ewing’s sarcoma/PNET has diagnostic genetical ﬁndings.
The most common translocation is t(11;22) (q24;q12) with
EWSR1-FLI1 genfusion (>90%) [3, 6, 7]. EWSR1 rearrange-
ment can occur in other malignant tumours. In our case, the
most relevant diﬀerential diagnosis is the very rare desmo-
plastic small round-cell tumour which can look much like
Ewing’s sarcoma morphologically. When FISH shows this
rearrangement, PCR can help determine which tumour it is
when the morphological ﬁndings are similar.
There are diﬀerent views of the value of adjuvant chem-
otherapy in this group of patients. Several studies show the
beneﬁt of adjuvant chemotherapy [8–10]w h i l s to t h e r sﬁ n d
no clinical improvement [3]. Our patient was givensix cycles
of chemotherapy, but it is still too early to determine the
outcome of his treatment.
Ewing’s sarcoma/PNET of the kidney is an aggressive
tumour, and 5-year disease-free survival is reported around
45–55% [11–15]. Mukkunda et al. [16] found in their analy-
sis of 7 patients with renal Ewing’s sarcoma and with median
follow-up of 36 months (range from 5 to 149), a median
disease-free survival in patients with nonmetastatic disease
of30.35months(range from 5.1to 149)with a 5-year overall
survival rate of 42%. All PNETs show a 5-year survival rate
of 58–61% with a median survival of 120 months [5]. In
comparison, Gupta et al. [17] found in their analysis of adult
patients with localised Ewing’s sarcoma in bone and soft
tissue a 3-year event-free survival of 43% +/− 13%. Further
follow-up of these patients is required to rule out relapse
of the tumour as Ewing’s sarcomas are highly aggressive
tumours.
5.Conclusion
Ewing’s sarcoma of the kidney is in itself a rare diagnosis.
This tumour is generally seen in young adults in bone and
soft tissue of the extremities and pelvis. This case shows that
Ewing’s sarcomas in the kidney may occur in all ages.
The treatment options for the diﬀerent types of renal
tumours are vastly diﬀerent and the need for a correct diag-
nosis is, therefore, vital. The best practice treatment today is
based on both surgical dissection and chemotherapy.
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